Read by QxMD icon Read

Anemia in HI

Qing-Bing Zhou, Xiao-Hong Yang, Hong-Zhi Wang, De-Xiu Wang, Yong-Gang Xu, Xiao-Mei Hu, Feng-Qin Xu, Rou Ma
OBJECTIVE: To explore the effect of Qinghuang Powder (QHP, ) combined with Bupi Yishen Decoction (BPYS, ) on myelodysplastic syndromes (MDS) patients with refractory cytopenia with multilineage dysplasia (RCMD) and determine the change of DNA methylation in MDS-RCMD patients after the treatment of Chinese medicine formula. METHODS: All 308 MDS-RCMD patients were treated with QHP combined with BPYS for 2 months at least, absolute neutrophil count (ANC), hemoglobin (Hb), platelets (PLT), primitive bone marrow cells and chromosome karyotype were chosen as the main evaluation indexes to analyze the treatment effect according to criteria from the MDS International Working Group...
March 2, 2018: Chinese Journal of Integrative Medicine
Meng Wang, Hao-Hao Han, Rong Guo, Yan-Fang Liu, Zhong-Xing Jiang, Hui Sun
OBJECTIVE: To investigate the clinical efficacy of low-dose decitabine combined with CAG regimen in patients with myelodysplastic syndrome-refractory anemia with excess blasts (MDS-RAEB) through retrospective analysis. METHODS: Thirty-six patients with MDS-RAEB who ever received low-dose decitabine combined with CAG regimen were enrolled into decitabine + CAG group and 40 patients with MDS-RAEB treated by decitabine alone in our center were enolled into the control group...
October 2017: Zhongguo Shi Yan Xue Ye Xue za Zhi
Dafna Gilboa, Yasmin Haim-Ohana, Naamit Deshet-Unger, Nathalie Ben-Califa, Sahar Hiram-Bab, Debby Reuveni, Ehud Zigmond, Max Gassmann, Yankel Gabet, Chen Varol, Drorit Neumann
Erythropoietin (EPO) is the main hormone driving mammalian erythropoiesis, with activity mediated via the surface receptor, EPO-R, on erythroid progenitor cells. Recombinant human EPO is currently used clinically for the treatment of anemia in patients with end-stage renal disease, and in certain cancer patients suffering from anemia induced either by the tumor itself or by chemotherapy. EPO-R expression is also detected in non-erythroid cells, including macrophages present in the peritoneum, spleen, and bone marrow (BM)...
September 4, 2017: Scientific Reports
Joaquin Sanchez-Garcia, Jose Falantes, Angeles Medina Perez, Francisca Hernandez-Mohedo, Lourdes Hermosin, Angeles Torres-Sabariego, Alicia Bailen, Jesus M Hernandez-Sanchez, María Solé Rodriguez, Francisco Javier Casaño, Cristina Calderon, Maria Labrador, Maria Vahí, Josefina Serrano, Eva Lumbreras, Jesus Maria Hernández-Rivas
In this prospective trial, the efficacy of azacitidine in lower-risk myelodysplastic syndromes (LR-SMD) lacking del(5q) was compared to best supportive care (BSC) at 1:1. The primary endpoint was the achievement of erythroid hematologic improvement (HI-E) after nine cycles. Thirty-six patients received at least ≥1 cycle. HI-E was confirmed 44.4% randomized to Aza and in 5.5% of patients receiving BSC (p < .01). After entry in Aza extension period, transfusion independence was achieved in all Aza responders with a median duration of 50 weeks (range: 17-231)...
May 2018: Leukemia & Lymphoma
U Platzbecker, A Symeonidis, E N Oliva, J S Goede, M Delforge, J Mayer, B Slama, S Badre, E Gasal, B Mehta, J Franklin
The use of darbepoetin alfa to treat anemia in patients with lower-risk myelodysplastic syndromes (MDS) was evaluated in a phase 3 trial. Eligible patients had low/intermediate-1 risk MDS, hemoglobin ⩽10 g/dl, low transfusion burden and serum erythropoietin (EPO) ⩽500 mU/ml. Patients were randomized 2:1 to receive 24 weeks of subcutaneous darbepoetin alfa 500 μg or placebo every 3 weeks (Q3W), followed by 48 weeks of open-label darbepoetin alfa. A total of 147 patients were randomized, with median hemoglobin of 9...
September 2017: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
Nan-Hung Hsieh, Shun-Hui Chung, Szu-Chieh Chen, Wei-Yu Chen, Yi-Hsien Cheng, Yi-Jun Lin, Su-Han You, Chung-Min Liao
BACKGROUND: Lead-exposed workers may suffer adverse health effects under the currently regulated blood lead (BPb) levels. However, a probabilistic assessment about lead exposure-associated anemia risk is lacking. The goal of this study was to examine the association between lead exposure and anemia risk among factory workers in Taiwan. METHODS: We first collated BPb and indicators of hematopoietic function data via health examination records that included 533 male and 218 female lead-exposed workers between 2012 and 2014...
May 5, 2017: BMC Public Health
Masaaki Adachi, Kimiyoshi Mitsuhashi, Hiroyuki Matsuda, Junko Watanabe, Katsuya Nakanishi
Fournier's gangrene (FG) is a fulminant infective necrotizing fasciitis, which includes the genital, perineal, and perianal regions. A 77-year-old man had previously been diagnosed as having diabetes mellitus (DM) and was treated with pioglitazone (15 mg) and miglitol (150 mg). He developed sudden perineal discomfort, fever with painful penile, and scrotal edema, subsequently leading to urinary retention. According to physical examination and CT scan results for the swollen penis and scrotum, he was diagnosed with FG...
2017: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
Xin-Yue Lian, Zhi-Hui Zhang, Zhao-Qun Deng, Pin-Fang He, Dong-Ming Yao, Zi-Jun Xu, Xiang-Mei Wen, Lei Yang, Jiang Lin, Jun Qian
BACKGROUND: Lenalidomide could effectively induce red blood cell (RBC) transfusion independence (TI) in patients with lower-risk (Low/Intermediate-1) myelodysplastic syndrome (MDS) with or without 5q deletion. However whether lenalidomide ultimately improves the overall survival (OS) of lower-risk MDS patients and reduces the progression to AML remains controversial. METHOD: A meta-analysis was conducted to examine the efficacy and safety of lenalidomide in the treatment of lower-risk MDS...
2016: PloS One
Zi-Wei Wang, Li-Jun Yang, Ying-Xue Ding, Yan-Zhong Chang, Hong Cui
This study aimed to investigate the role of iron in the occurrence and development of hypoxic-ischemic brain injury (HIBI) in immature rat models using 3-day-old Sprague Dawley rats. Normal control (NC), hypoxic-ischemic (HI), anemia, HI + ischemia, early iron treatment and late iron treatment groups were established. Rat brain tissue sections were stained with hematoxylin and eosin and pathologically evaluated. Iron content and mRNA expression levels of iron regulatory protein 2 (IRP2) and transferrin receptor in the brain tissues were measured...
September 2016: Experimental and Therapeutic Medicine
Shahram Kordasti, Benedetta Costantini, Thomas Seidl, Pilar Perez Abellan, Marc Martinez Llordella, Donal McLornan, Kirsten E Diggins, Austin Kulasekararaj, Cinzia Benfatto, Xingmin Feng, Alexander Smith, Syed A Mian, Rossella Melchiotti, Emanuele de Rinaldis, Richard Ellis, Nedyalko Petrov, Giovanni A M Povoleri, Sun Sook Chung, N Shaun B Thomas, Farzin Farzaneh, Jonathan M Irish, Susanne Heck, Neal S Young, Judith C W Marsh, Ghulam J Mufti
Idiopathic aplastic anemia (AA) is an immune-mediated and serious form of bone marrow failure. Akin to other autoimmune diseases, we have previously shown that in AA regulatory T cells (Tregs) are reduced in number and function. The aim of this study was to further characterize Treg subpopulations in AA and investigate the potential correlation between specific Treg subsets and response to immunosuppressive therapy (IST) as well as their in vitro expandability for potential clinical use. Using mass cytometry and an unbiased multidimensional analytical approach, we identified 2 specific human Treg subpopulations (Treg A and Treg B) with distinct phenotypes, gene expression, expandability, and function...
September 1, 2016: Blood
Jingya Wang, Tiejun Qin, Zefeng Xu, Yue Zhang, Hongli Zhang, Liwei Fang, Lijuan Pan, Naibo Hu, Shiqiang Qu, Bing Li, Zhijian Xiao
OBJECTIVE: To investigate the long- term outcome of cyclosporin A (CsA) combined with thalidomide regime for Chinese patients with IPSS low/intermediate- 1 myelodysplastic syndromes (MDS) without del(5q)and the predictive variables which could impact the response to the therapy. METHODS: Seventy-six MDS patients who were treated with these drugs at a single institute in China were retrospectively analyzed. The polymorphism of cereblon gene, rs1672753, was detected in patients of this cohort by PCR and direct sequencing...
November 2015: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
Zhaojun Zhang, Haibo Jia, Qian Zhang, Yang Wan, Binfeng Song, Qiong Jia, Hanzhi Liu, Xiaofan Zhu, Xiangdong Fang
To comprehensively reflect the roles of Rpl11 on the transcriptome of zebrafish model of Diamond-Blackfan Anemia (DBA), we performed whole-genome transcriptome sequencing on the Illumina Hi-Seq 2000 sequencing platform. Two different transcriptomes of zebrafish Rpl11-deficient and control Morpholino (Mo) embryos were collected and analyzed. The experimental design and methods, including sample preparation, RNA-Seq data evaluation and treatment, were described in details so that representative high-throughput sequencing data were acquired for assessing the actual impacts of Rpl11 on zebrafish embryos...
December 2014: Genomics Data
Sameh Gaballa, Neil Palmisiano, Onder Alpdogan, Matthew Carabasi, Joanne Filicko-O'Hara, Margaret Kasner, Walter K Kraft, Benjamin Leiby, Ubaldo Martinez-Outschoorn, William O'Hara, Barbara Pro, Shannon Rudolph, Manish Sharma, John L Wagner, Mark Weiss, Neal Flomenberg, Dolores Grosso
Haploidentical stem cell transplantation (SCT) offers a transplantation option to patients who lack an HLA-matched donor. We developed a 2-step approach to myeloablative allogeneic hematopoietic stem cell transplantation for patients with haploidentical or matched related (MR) donors. In this approach, the lymphoid and myeloid portions of the graft are administered in 2 separate steps to allow fixed T cell dosing. Cyclophosphamide is used for T cell tolerization. Given a uniform conditioning regimen, graft T cell dose, and graft-versus-host disease (GVHD) prophylaxis strategy, we compared immune reconstitution and clinical outcomes in patients undergoing 2-step haploidentical versus 2-step MR SCT...
January 2016: Biology of Blood and Marrow Transplantation
Harpreet Kochhar, Chantal S Leger, Heather A Leitch
Background. Hematologic improvement (HI) occurs in some patients with acquired anemias and transfusional iron overload receiving iron chelation therapy (ICT) but there is little information on transfusion status after stopping chelation. Case Report. A patient with low IPSS risk RARS-T evolved to myelofibrosis developed a regular red blood cell (RBC) transfusion requirement. There was no response to a six-month course of study medication or to erythropoietin for three months. At 27 months of transfusion dependence, she started deferasirox and within 6 weeks became RBC transfusion independent, with the hemoglobin normalizing by 10 weeks of chelation...
2015: Case Reports in Hematology
Jizhou Zhang, Qingqing Wu, Jun Shi, Meili Ge, Xingxin Li, Yingqi Shao, Jianfeng Yao, Yizhou Zheng
OBJECTIVE: Recently enhanced T-helper type 17 (Th17) immune responses and deficient CD4(+) CD25(hi) FoxP3(+) regulatory T cells (Tregs) have been reported in acquired aplastic anemia (AA). Interleukin-21 (IL-21), a CD4(+) T-cell-derived proinflammatory cytokine, modulates the balance between Th17 cells and Tregs. However, its role in AA remains unclear. METHODS: IL-21 gene expression was examined by quantitative real-time PCR. Cytokines in plasma and cell culture supernatants were detected by ELISA...
July 2015: European Journal of Haematology
Kirtan Nautiyal, Rui Li, Sarvari Yellapragada, Perumal Thiagarajan, Martha Mims, Gustavo Rivero
Refractoriness to growth factor therapy is commonly associated with inferior outcome in patients with low-risk myelodysplastic syndrome (LR-MDS) who require treatment for cytopenias. However, the mechanisms leading to refractoriness are unknown. Here we describe a clinically depressed 74-year-old male with refractory cytopenia with multilineage dysplasia (RCMD) and documented growth factor refractory anemia after erythropoeisis stimulating agent (ESA) therapy, who attained transfusion and growth factor independence after the addition of sertraline to his medication regimen...
2015: Leukemia Research Reports
Juan Ma, Xiaosha Wen, Fengfeng Mo, Xiaoli Wang, Zhilei Shen, Min Li
Many controversies persist with respect to the dosage and therapeutic duration concerning iron deficiency anemia (IDA) treatment. To identify the most suitable cure, this study evaluated the effect of iron supplementation with different doses and for different time periods in rats with iron deficiency anemia. The rats were randomly divided into five groups [normal control (NC), low- iron diet control (LC), normal doses of iron group (NI), middle dose of iron group (MI), and high dose of iron group (HI)]. Each group was subdivided into two subgroups (2 and 4 weeks)...
December 2014: Biological Trace Element Research
Lihua Zhu, Xiang Bai, Shiyu Wang, Yan Hu, Ting Wang, Lijuan Qian, Li Jiang
BACKGROUND: Recombinant human erythropoietin (rh-EPO) has been used as a drug to treat premature infant anemia for over a decade. In addition to its erythropoietic effect, rh-EPO has also been reported to have protective effects against brain injury. OBJECTIVES: Our aim was to evaluate the levels of angiogenesis-related cells (CD34+ cells) and angiogenic factors (vascular endothelial growth factor, VEGF, and angiopoietin-1, Ang-1) in a neonatal rat model of cerebral unilateral hypoxia-ischemia (HI) and to identify the effects of rh-EPO on angiogenic responses...
2014: Neonatology
Meng-Ying Zhang, Jie Ma, Hui Sun, Xin-Sheng Xie, Chong Wang, Shuai Liu, Tao Li
The purpose of this study was retrospectively to analyze the peripheral blood lymphocyte subset distribution in patients with low or intermediate risk myelodysplastic syndromes (IPSS ≤ 1.0) and chronic aplastic anemia (CAA), and their hematological changes of peripheral blood after treatment, so as to understand differences and their relation with early treatment response. The lymphocyte subsets in peripheral blood of 67 patient with low or intermediate risk MDS (IPSS ≤ 1.0), 54 patients with CAA and 73 healthy individuals were analyzed by flow cytometry...
April 2014: Zhongguo Shi Yan Xue Ye Xue za Zhi
Tze Pin Ng, Liang Feng, Ma Shwe Zin Nyunt, Anis Larbi, Keng Bee Yap
IMPORTANCE: Currently there is no risk factor scale that identifies older persons at risk of frailty. OBJECTIVES: In this study, we identified significant multisystem risk factors of frailty, developed a simple frailty risk index, and evaluated it for use in primary care on an external validation cohort of community-living older persons. DESIGN, SETTING, AND PARTICIPANTS: We used cross-sectional data of 1685 older adults aged 55 and older in the Singapore Longitudinal Ageing Studies (SLAS) to identify 13 salient risk factors among 40 known and putative risk factors of the frailty phenotype (weakness, slowness, low physical activity, weight loss, and exhaustion)...
September 2014: Journal of the American Medical Directors Association
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"